Between seven and 10 million people worldwide have Parkinson’s disease, a progressive neurological condition marked by tremor, rigidity and the gradual loss of voluntary movement, along with a host of other symptoms such as loss of sense of smell, cognitive issues, depression, constipation, trouble sleeping and pain.
Currently, there is no cure for Parkinson’s and there are no treatment strategies that slow or stop disease progression. But thanks to recent advances, scientists in the Institute’s Center for Neurodegenerative Science and collaborators around the world are narrowing down the factors that contribute to the disease and working to translate these findings into new, life-changing therapies.
The Center also is investigating other diseases caused by progressive damage to the brain, including Alzheimer’s disease and multiple system atrophy (MSA), as well as the biological basis of depression.
Pai S, Li P, Killinger B, Marshall L, Jia P, Liao J, Petronis A, Szabó P, Labrie V. 2019. Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. Nat Comm.
Chen X, Kordich JK, Williams ET, Levine N, Cole-Strauss A, Marshall L, Labrie V, Ma J, Lipton JW, Moore DJ. 2019. Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A.
Brundin P, Coetzee GA. 2019. Genetically engineered stem cell-derived neurons can be rendered resistant to alpha-synuclein aggregate pathology. Eur J Neurosci.
Wang Z, Yuan J, Shen P Abskharon R, Lang L, Dang J, Adornato A, Xu L,Chen J, Feng J, Moudjou M, Kitamoto T, Langveld J, Appleby B, Ma J, Kong Q, Petersen RB, Zou WQ, Cui L. 2019. In vitro seeding activity of glycoform-deficient prions from variably protease-sensitive prionopathy and familial CJD associated PrPV180I mutation. Mol Neurobiol.
Oh G, Koncevicius K, Ebrahimi S, Carlucci M, Groot DE, Nair A, Zhang A, Krisciunas A, Oh ES, Labrie V, Wong AHC, Gordeviscius J, Jia P, Susic M, Petronis A. 2019. Circadian oscillations of cytosine modification in humans contribute to epigenetic variability, aging and complex disease. Genome Biol 20(1):2.
Johnson ME, Stecher B, Labrie V, Brundin L, Brundin P. 2018. Triggers, facilitators and aggravators: Redefining Parkinson’s disease pathogenesis. Trends Neurosci.
Save the date for Grand Challenges in Parkinson’s Disease and Rallying to the Challenge!
This year’s symposium and parallel patient meeting will be held Aug. 21–22, and will address understanding genetic risk in Parkinson’s. Learn more at grandchallengesinpd.org.